BR112016030422A2 - aplicação tópica de um anticorpo anti-hsv - Google Patents

aplicação tópica de um anticorpo anti-hsv

Info

Publication number
BR112016030422A2
BR112016030422A2 BR112016030422A BR112016030422A BR112016030422A2 BR 112016030422 A2 BR112016030422 A2 BR 112016030422A2 BR 112016030422 A BR112016030422 A BR 112016030422A BR 112016030422 A BR112016030422 A BR 112016030422A BR 112016030422 A2 BR112016030422 A2 BR 112016030422A2
Authority
BR
Brazil
Prior art keywords
hsv
antibody
antigen
herpes simplex
topical application
Prior art date
Application number
BR112016030422A
Other languages
English (en)
Inventor
Jäger Dirk
Krauss Jürgen
Arndt Michaela
Original Assignee
Heidelberg Immunotherapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Immunotherapeutics Gmbh filed Critical Heidelberg Immunotherapeutics Gmbh
Publication of BR112016030422A2 publication Critical patent/BR112016030422A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

é descrito um anticorpo anti-hsv ou um fragmento de ligação ao antígeno desse para uso no tratamento de uma infecção aguda do tecido da mucosa ou epiderme em um indivíduo, causada por hsv-1 ou hsv-2 selecionado do grupo que consiste em herpes simples labial, herpes simples genital, infecção por herpes simples crônica ou disseminada, herpes gladiatorum e eczema herpético, em que o dito anticorpo é para ser administrado topicamente, assim como uma composição farmacêutica que compreende uma quantidade eficaz do dito anticorpo ou do fragmento de ligação ao antígeno desse e pelo menos um excipiente farmaceuticamente aceitável.
BR112016030422A 2014-06-26 2015-06-25 aplicação tópica de um anticorpo anti-hsv BR112016030422A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14174174 2014-06-26
PCT/EP2015/064378 WO2015197763A1 (en) 2014-06-26 2015-06-25 Topical application for an anti-hsv antibody

Publications (1)

Publication Number Publication Date
BR112016030422A2 true BR112016030422A2 (pt) 2017-10-24

Family

ID=51032986

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030422A BR112016030422A2 (pt) 2014-06-26 2015-06-25 aplicação tópica de um anticorpo anti-hsv

Country Status (14)

Country Link
US (2) US11267871B2 (pt)
EP (1) EP3160997B1 (pt)
JP (1) JP6649284B2 (pt)
KR (1) KR102622280B1 (pt)
CN (2) CN106488931B (pt)
AU (1) AU2015279212B2 (pt)
BR (1) BR112016030422A2 (pt)
CA (1) CA2950489C (pt)
ES (1) ES2843277T3 (pt)
NZ (1) NZ726168A (pt)
RU (1) RU2703903C2 (pt)
SG (1) SG11201610320RA (pt)
WO (1) WO2015197763A1 (pt)
ZA (1) ZA201607813B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
CN110225781B (zh) * 2017-01-09 2022-05-17 辉诺生物医药科技（杭州）有限公司 噻唑衍生物及其应用
JP7145862B2 (ja) * 2017-08-30 2022-10-03 Ｋｍバイオロジクス株式会社 抗ＨＳＶ ｇＢモノクローナル抗体又はその抗原結合断片
WO2020041911A1 (es) * 2018-08-28 2020-03-05 Pontificia Universidad Catolica De Chile Anticuerpo monoclonal 11b2c7 o fragmento del mismo, que reconoce específicamente virus herpes simple 1 y 2
US20210347856A1 (en) * 2018-08-28 2021-11-11 Pontificia Universidad Catolica De Chile Monoclonal antibody 14f5f6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2
JP2022525535A (ja) * 2019-03-19 2022-05-17 アルベルト・アインシュタイン・カレッジ・オブ・メディシン 単純ヘルペスウイルス感染の予防及び処置のためのモノクローナル抗体
WO2022002802A1 (en) * 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa HSV gEgI HETERODIMER ANTIBODIES
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2023166081A1 (en) * 2022-03-02 2023-09-07 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
WO2024046476A1 (en) * 2022-09-02 2024-03-07 United BioPharma, Inc. Treatment of herpes simplex virus infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018634A1 (en) * 1994-01-04 1995-07-13 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
WO2001023414A2 (en) * 1999-09-30 2001-04-05 University Of Washington Immunologically significant herpes simplex virus antigens
NZ524523A (en) * 2000-08-03 2006-02-24 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals
US20070274997A1 (en) * 2003-07-25 2007-11-29 Anthony Simmons Compositions and Methods for Herpes Simplex Prophylaxis and Treatment
US6984492B2 (en) * 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
PL2248825T3 (pl) * 2009-05-04 2013-04-30 Ribovax Biotechnologies Sa Fragmenty przeciwciała wiążące antygen do zastosowania w leczeniu i diagnozowaniu chorób oczu
EP2308895A1 (en) * 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV antibody
US20140302062A1 (en) * 2011-04-08 2014-10-09 U.S. Army Medical Research And Materiel Command Herpes simplex virus

Also Published As

Publication number Publication date
AU2015279212B2 (en) 2020-08-20
NZ726168A (en) 2022-05-27
US11267871B2 (en) 2022-03-08
KR20170020423A (ko) 2017-02-22
US20220169705A1 (en) 2022-06-02
CN106488931B (zh) 2021-12-28
CN114306596A (zh) 2022-04-12
CA2950489A1 (en) 2015-12-30
RU2017102387A (ru) 2018-07-26
KR102622280B1 (ko) 2024-01-08
AU2015279212A1 (en) 2016-12-01
RU2017102387A3 (pt) 2018-07-26
CA2950489C (en) 2022-09-20
US20170152304A1 (en) 2017-06-01
WO2015197763A1 (en) 2015-12-30
JP2017520572A (ja) 2017-07-27
ES2843277T3 (es) 2021-07-16
AU2015279212A2 (en) 2017-04-27
EP3160997B1 (en) 2020-10-28
SG11201610320RA (en) 2017-01-27
RU2703903C2 (ru) 2019-10-22
EP3160997A1 (en) 2017-05-03
ZA201607813B (en) 2018-05-30
CN106488931A (zh) 2017-03-08
JP6649284B2 (ja) 2020-02-19

Similar Documents

Publication Publication Date Title
BR112016030422A2 (pt) aplicação tópica de um anticorpo anti-hsv
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112017026294A2 (pt) formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição.
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
DOP2014000260A (es) Compuestos d-aminoácidos para enfermedad hepática
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
BR112015025709A2 (pt) monoterapia com gla para uso em tratamento de câncer
BR112015000615A8 (pt) Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112015021392A2 (pt) uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112012009432A2 (pt) anticorpo anti-hsv
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015030774A2 (pt) novos compostos para o tratamento de câncer
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: HEIDELBERG IMMUNOTHERAPEUTICS GMBH (DE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]